"ERG1 Potassium Channel" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
One of three members of the ether-a-go-go (EAG) POTASSIUM CHANNELS gene family comprising ether-a-go-go (eag), eag-like (elk) and eag-related (erg) subfamilies. Ether-a-go-go-related gene 1 (ERG1) also known as KCNH2, encodes the pore-forming subunit of a rapidly activating-delayed rectifier potassium channel that plays an essential role in the final repolarization of ventricular action potential. Loss-of-function mutations in human hERG1 is associated with life-threatening ARRHYTHMIA.
|ERG1 Potassium Channel
- ERG1 Potassium Channel
- Channel, ERG1 Potassium
- Potassium Channel, ERG1
- Potassium Voltage-Gated Channel, Subfamily H, Member 2
- Ether-A-Go-Go-Related Potassium Channel 1
- Ether A Go Go Related Potassium Channel 1
Kv11.1 Protein-Potassium Channel
- Kv11.1 Protein-Potassium Channel
- Channel, Kv11.1 Protein-Potassium
- Kv11.1 Protein Potassium Channel
- Protein-Potassium Channel, Kv11.1
Below are MeSH descriptors whose meaning is more general than "ERG1 Potassium Channel".
Below are MeSH descriptors whose meaning is more specific than "ERG1 Potassium Channel".
This graph shows the total number of publications written about "ERG1 Potassium Channel" by people in this website by year, and whether "ERG1 Potassium Channel" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
|Year||Major Topic||Minor Topic||Total|
To return to the timeline, click here.
Below are the most recent publications written about "ERG1 Potassium Channel" by people in Profiles.
Roder K, Kabakov A, Moshal KS, Murphy KR, Xie A, Dudley S, Turan NN, Lu Y, MacRae CA, Koren G. Trafficking of the human ether-a-go-go-related gene (hERG) potassium channel is regulated by the ubiquitin ligase rififylin (RFFL). J Biol Chem. 2019 01 04; 294(1):351-360.
Liu Z, Hutt JA, Rajeshkumar B, Azuma Y, Duan KL, Donahue JK. Preclinical efficacy and safety of KCNH2-G628S gene therapy for postoperative atrial fibrillation. J Thorac Cardiovasc Surg. 2017 11; 154(5):1644-1651.e8.
Kane DA, Triedman J. Post-mortem genetic testing in a family with long-QT syndrome and hypertrophic cardiomyopathy. Cardiovasc Pathol. 2014 Mar-Apr; 23(2):107-9.
Chen T, Benmohamed R, Kim J, Smith K, Amante D, Morimoto RI, Kirsch DR, Ferrante RJ, Silverman RB. ADME-guided design and synthesis of aryloxanyl pyrazolone derivatives to block mutant superoxide dismutase 1 (SOD1) cytotoxicity and protein aggregation: potential application for the treatment of amyotrophic lateral sclerosis. J Med Chem. 2012 Jan 12; 55(1):515-27.
Amit G, Kikuchi K, Greener ID, Yang L, Novack V, Donahue JK. Selective molecular potassium channel blockade prevents atrial fibrillation. Circulation. 2010 Jun 01; 121(21):2263-70.
Donahue JK, Sasano T, Kelemen K. Gene therapy approaches to ventricular tachyarrhythmias. J Electrocardiol. 2007 Nov-Dec; 40(6 Suppl):S187-91.
Sasano T, McDonald AD, Kikuchi K, Donahue JK. Molecular ablation of ventricular tachycardia after myocardial infarction. Nat Med. 2006 Nov; 12(11):1256-8.